Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 28, 2020 | Series C | $100M | 2 | — | — | Detail |
Feb 25, 2019 | Series B | $85M | 3 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
King Star Capital | — | Series C |
Lilly Asia Ventures | — | Series C |
Chengdu Miaoji Medical Technology | — | Series B |